QIPT vs. CLPT, OBIO, DRTS, PROF, TELA, STIM, DCTH, ALUR, KRMD, and BLUA
Should you be buying Quipt Home Medical stock or one of its competitors? The main competitors of Quipt Home Medical include ClearPoint Neuro (CLPT), Orchestra BioMed (OBIO), Alpha Tau Medical (DRTS), Profound Medical (PROF), TELA Bio (TELA), Neuronetics (STIM), Delcath Systems (DCTH), Allurion Technologies (ALUR), KORU Medical Systems (KRMD), and BlueRiver Acquisition (BLUA). These companies are all part of the "surgical & medical instruments" industry.
ClearPoint Neuro (NASDAQ:CLPT) and Quipt Home Medical (NASDAQ:QIPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.
Quipt Home Medical has a net margin of -1.50% compared to Quipt Home Medical's net margin of -92.21%. ClearPoint Neuro's return on equity of -3.57% beat Quipt Home Medical's return on equity.
ClearPoint Neuro has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Quipt Home Medical has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Quipt Home Medical has higher revenue and earnings than ClearPoint Neuro. Quipt Home Medical is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.
Quipt Home Medical received 4 more outperform votes than ClearPoint Neuro when rated by MarketBeat users. However, 86.96% of users gave ClearPoint Neuro an outperform vote while only 82.76% of users gave Quipt Home Medical an outperform vote.
ClearPoint Neuro presently has a consensus price target of $12.00, indicating a potential upside of 130.77%. Quipt Home Medical has a consensus price target of $10.00, indicating a potential upside of 169.54%. Given ClearPoint Neuro's higher possible upside, analysts clearly believe Quipt Home Medical is more favorable than ClearPoint Neuro.
In the previous week, ClearPoint Neuro had 4 more articles in the media than Quipt Home Medical. MarketBeat recorded 5 mentions for ClearPoint Neuro and 1 mentions for Quipt Home Medical. Quipt Home Medical's average media sentiment score of 0.53 beat ClearPoint Neuro's score of 0.40 indicating that ClearPoint Neuro is being referred to more favorably in the media.
30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 42.9% of Quipt Home Medical shares are owned by institutional investors. 6.1% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 4.2% of Quipt Home Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
ClearPoint Neuro and Quipt Home Medical tied by winning 9 of the 18 factors compared between the two stocks.
Get Quipt Home Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for QIPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QIPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quipt Home Medical Competitors List
Related Companies and Tools
